Management of Viral Upper Respiratory Tract Infections

Core Symptomatic Treatment

The American Academy of Family Physicians recommends prescribing acetaminophen or ibuprofen for pain, fever, and inflammation in patients with viral upper respiratory tract infections 1
The American College of Physicians suggests recommending adequate hydration and rest as foundational supportive care for patients with viral upper respiratory tract infections 1, 2
Nasal saline irrigation may be considered for persistent nasal congestion in patients with viral upper respiratory tract infections, providing minor symptom improvement 1, 2
For bothersome dry cough, the American Academy of Pediatrics recommends prescribing dextromethorphan or codeine 1, 2

The Infectious Diseases Society of America advises against prescribing antibiotics for uncomplicated viral upper respiratory tract infections, as they are ineffective against viral illness and do not prevent lower respiratory tract infections 1, 3
The American Academy of Family Physicians recommends avoiding the use of mucolytics, expectorants, or bronchodilators in patients with uncomplicated viral upper respiratory tract infections 1

The American College of Physicians suggests considering amoxicillin for patients with high fever persisting beyond 3 days with bothersome cough, which may indicate bacterial superinfection 1, 2
For confirmed bacterial complications, such as acute bacterial rhinosinusitis, the Infectious Diseases Society of America recommends amoxicillin-clavulanate or second-generation or third-generation oral cephalosporins for 7-10 days 1, 3
For streptococcal pharyngitis, the American Academy of Pediatrics recommends a 10-day treatment course with antibiotics, only if test or culture is positive 1

The American Academy of Family Physicians advises patients to return if symptoms persist beyond 3 weeks, fever exceeds 4 days, dyspnea worsens, or patient's condition deteriorates 1
The European Respiratory Society recommends considering chest imaging if symptoms persist or worsen to rule out parenchymal lung disease 1, 2, 4

The American College of Physicians suggests that patients with risk factors such as age ≥65 years, chronic cardiac or pulmonary diseases, diabetes mellitus, or chronic renal diseases require enhanced surveillance 1, 2

The Infectious Diseases Society of America recommends that immunocompromised patients, such as those with hematopoietic stem cell transplant or leukemia, require viral testing and may need specific antiviral therapy, including ribavirin 5, 6, 7, 8